biostudies-literatureUnknown107(3)Pecuchet N<h4>Background</h4>Inter-patient pharmacokinetic variability can lead to suboptimal drug exposure, and therefore might impact the efficacy of sorafenib. This study reports long-term pharmacokinetic monitoring of patients treated with sorafenib and a retrospective pharmacodynamic/pharmacokinetic analysis in melanoma patients.<h4>Patients and methods</h4>Heavily pretreated patients with stage IV melanoma were started on sorafenib 400 mg twice daily (bid). In the absence of limiting toxicity, dose escalation of 200 mg bid levels was done every 2 weeks. Plasma sorafenib measurement was performed at each visit, allowing a retrospective pharmacodynamic/pharmacokinetic analysis for safety and efficacy.<h4>Results</h4>In all, 19 of 30 patients underwent dose escalation over 400 mg bid, and 28 wereBritish journal of cancer455-61https://www.ebi.ac.uk/biostudies/studies/S-EPMC3405224biostudies-literatureSorafenib in advanced melanoma: a critical role for pharmacokinetics?PMC3405224Pecuchet NBillemont BGoldwasser FFranck NAvril MFTod MCoriat RLebbe CViguier MMir OBlanchet BfalseSorafenib in advanced melanoma: a critical role for pharmacokinetics?<h4>Background</h4>Inter-patient pharmacokinetic variability can lead to suboptimal drug exposure, and therefore might impact the efficacy of sorafenib. This study reports long-term pharmacokinetic monitoring of patients treated with sorafenib and a retrospective pharmacodynamic/pharmacokinetic analysis in melanoma patients.<h4>Patients and methods</h4>Heavily pretreated patients with stage IV melanoma were started on sorafenib 400 mg twice daily (bid). In the absence of limiting toxicity, dose escalation of 200 mg bid levels was done every 2 weeks. Plasma sorafenib measurement was performed at each visit, allowing a retrospective pharmacodynamic/pharmacokinetic analysis for safety and efficacy.<h4>Results</h4>In all, 19 of 30 patients underwent dose escalation over 400 mg bid, and 28 were2012-01-01T00:00:00Z2012 Jul2025-04-18T23:13:55.225Z2019-03-27T00:55:58ZS-EPMC34052242276714610.1038/bjc.2012.287